

Emmanuel Bachy

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8471259/publications.pdf>

Version: 2024-02-01

143
papers

3,846
citations

147566

31
h-index

149479

56
g-index

151
all docs

151
docs citations

151
times ranked

5444
citing authors

#	ARTICLE	IF	CITATIONS
1	A multiprotein supercomplex controlling oncogenic signalling in lymphoma. <i>Nature</i> , 2018, 560, 387-391.	13.7	276
2	Early event status informs subsequent outcome in newly diagnosed follicular lymphoma. <i>American Journal of Hematology</i> , 2016, 91, 1096-1101.	2.0	180
3	Antimicrobial Resistance in Gram-Negative Rods Causing Bacteremia in Hematopoietic Stem Cell Transplant Recipients: Intercontinental Prospective Study of the Infectious Diseases Working Party of the European Bone Marrow Transplantation Group. <i>Clinical Infectious Diseases</i> , 2017, 65, 1819-1828.	2.9	179
4	Sustained Progression-Free Survival Benefit of Rituximab Maintenance in Patients With Follicular Lymphoma: Long-Term Results of the PRIMA Study. <i>Journal of Clinical Oncology</i> , 2019, 37, 2815-2824.	0.8	173
5	CAR-HEMATOTOX: a model for CAR T-cell-related hematologic toxicity in relapsed/refractory large B-cell lymphoma. <i>Blood</i> , 2021, 138, 2499-2513.	0.6	160
6	Cause of Death in Follicular Lymphoma in the First Decade of the Rituximab Era: A Pooled Analysis of French and US Cohorts. <i>Journal of Clinical Oncology</i> , 2019, 37, 144-152.	0.8	142
7	A simplified scoring system in de novo follicular lymphoma treated initially with immunochemotherapy. <i>Blood</i> , 2018, 132, 49-58.	0.6	130
8	Role of up-front autologous stem-cell transplantation in peripheral T-cell lymphoma for patients in response after induction: an analysis of patients from LYSA centers. <i>Annals of Oncology</i> , 2018, 29, 715-723.	0.6	110
9	Early posttransplantation donor-derived invariant natural killer T-cell recovery predicts the occurrence of acute graft-versus-host disease and overall survival. <i>Blood</i> , 2012, 120, 2144-2154.	0.6	102
10	Outcomes of diffuse large B-cell lymphoma patients relapsing after autologous stem cell transplantation: an analysis of patients included in the CORAL study. <i>Bone Marrow Transplantation</i> , 2017, 52, 216-221.	1.3	102
11	Combination of romidepsin with cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated patients with peripheral T-cell lymphoma: a non-randomised, phase 1b/2 study. <i>Lancet Haematology</i> , 2015, 2, e160-e165.	2.2	95
12	ABVD (8 cycles) versus BEACOPP (4 escalated cycles +4 baseline): final results in stage III-IV low-risk Hodgkin lymphoma (IPS 0-2) of the LYSA H34 randomized trial. <i>Annals of Oncology</i> , 2014, 25, 1622-1628.	0.6	91
13	Romidepsin Plus CHOP Versus CHOP in Patients With Previously Untreated Peripheral T-Cell Lymphoma: Results of the Ro-CHOP Phase III Study (Conducted by LYSA). <i>Journal of Clinical Oncology</i> , 2022, 40, 242-251.	0.8	90
14	Commercial anti-CD19 CAR T cell therapy for patients with relapsed/refractory aggressive B cell lymphoma in a European center. <i>American Journal of Hematology</i> , 2020, 95, 1324-1333.	2.0	89
15	Targeting the HTLV-I-Regulated BATF3/IRF4 Transcriptional Network in Adult T Cell Leukemia/Lymphoma. <i>Cancer Cell</i> , 2018, 34, 286-297.e10.	7.7	88
16	FDG-PET-driven consolidation strategy in diffuse large B-cell lymphoma: final results of a randomized phase 2 study. <i>Blood</i> , 2017, 130, 1315-1326.	0.6	87
17	Consensus criteria for diagnosis, staging, and treatment response assessment of T-cell prolymphocytic leukemia. <i>Blood</i> , 2019, 134, 1132-1143.	0.6	81
18	Poor outcome of patients with COVID-19 after CAR T-cell therapy for B-cell malignancies: results of a multicenter study on behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party and the European Hematology Association (EHA) Lymphoma Group. <i>Leukemia</i> , 2021, 35, 3585-3588.	3.3	72

#	ARTICLE	IF	CITATIONS
19	Long-term follow up of the FL2000 study comparing CHVP-interferon to CHVP-interferon plus rituximab in follicular lymphoma. <i>Haematologica</i> , 2013, 98, 1107-1114.	1.7	70
20	Long-Term Follow-Up of Patients With Newly Diagnosed Follicular Lymphoma in the Prerituximab Era: Effect of Response Quality on Survival—A Study From the Groupe d'Etude des Lymphomes de l'Adulte. <i>Journal of Clinical Oncology</i> , 2010, 28, 822-829.	0.8	63
21	From hepatitis C virus infection to B-cell lymphoma. <i>Annals of Oncology</i> , 2018, 29, 92-100.	0.6	63
22	Description of neurotoxicity in a series of patients treated with CAR T-cell therapy. <i>Scientific Reports</i> , 2020, 10, 18997.	1.6	59
23	Clinical outcome of 27 imatinib mesylate-resistant chronic myelogenous leukemia patients harboring a T315I BCR-ABL mutation. <i>Haematologica</i> , 2007, 92, 1238-1241.	1.7	58
24	Autologous stem cell transplantation for relapsed/refractory diffuse large B-cell lymphoma: efficacy in the rituximab era and comparison to first allogeneic transplants. A report from the EBMT Lymphoma Working Party. <i>Bone Marrow Transplantation</i> , 2016, 51, 365-371.	1.3	43
25	Outcomes in patients treated with chimeric antigen receptor T-cell therapy who were admitted to intensive care (CARTTAS): an international, multicentre, observational cohort study. <i>Lancet Haematology</i> , 2021, 8, e355-e364.	2.2	43
26	Lenalidomide as salvage treatment for multiple myeloma relapsing after allogeneic hematopoietic stem cell transplantation: a report from the French Society of Bone Marrow and Cellular Therapy. <i>Haematologica</i> , 2013, 98, 776-783.	1.7	38
27	Integrative analysis of a phase 2 trial combining lenalidomide with CHOP in angioimmunoblastic T-cell lymphoma. <i>Blood Advances</i> , 2021, 5, 539-548.	2.5	38
28	Anti-PD1 antibody: a new approach to treatment of lymphomas. <i>Lancet Oncology</i> , 2014, 15, 7-8.	5.1	36
29	Maintaining calcineurin inhibition after the diagnosis of post-transplant lymphoproliferative disorder improves renal graft survival. <i>Kidney International</i> , 2014, 85, 182-190.	2.6	35
30	A matched case-control study of toxoplasmosis after allogeneic hematopoietic stem cell transplantation: still a devastating complication. <i>Clinical Microbiology and Infection</i> , 2016, 22, 636-641.	2.8	35
31	Phase 1 study of the oral histone deacetylase inhibitor abexinostat in patients with Hodgkin lymphoma, non-Hodgkin lymphoma, or chronic lymphocytic leukaemia. <i>Investigational New Drugs</i> , 2015, 33, 423-431.	1.2	33
32	HHV-6 infection after allogeneic hematopoietic stem cell transplantation: From chromosomal integration to viral co-infections and T-cell reconstitution patterns. <i>Journal of Infection</i> , 2016, 72, 214-222.	1.7	32
33	Allogeneic stem cell transplantation for patients with mantle cell lymphoma who failed autologous stem cell transplantation: a national survey of the SFGM-TC. <i>Bone Marrow Transplantation</i> , 2016, 51, 1184-1190.	1.3	31
34	Brentuximab vedotin in refractory or relapsed peripheral T-cell lymphomas: the French named patient program experience in 56 patients. <i>Haematologica</i> , 2016, 101, e103-e106.	1.7	30
35	Impact of Donor-Derived Invariant Natural Killer T (iNKT) Cell Reconstitution After Allogeneic Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2009, 114, 346-346.	0.6	30
36	Nodular lymphocyte predominant Hodgkin lymphoma: a Lymphoma Study Association retrospective study. <i>Haematologica</i> , 2015, 100, 1579-1586.	1.7	28

#	ARTICLE	IF	CITATIONS
37	Comparative toxicities of 3 platinum-containing chemotherapy regimens in relapsed/refractory lymphoma patients. <i>Hematological Oncology</i> , 2017, 35, 584-590.	0.8	28
38	Clinicopathological features and survival in EBV-positive diffuse large B-cell lymphoma not otherwise specified. <i>Blood Advances</i> , 2021, 5, 3227-3239.	2.5	28
39	Macrophage, mast cell and T lymphocyte infiltrations are independent predictive biomarkers of primary refractoriness or early relapse in classical Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2013, 54, 41-45.	0.6	26
40	Sarcoidosis and lymphoma: a comparative study. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2015, 108, 871-878.	0.2	25
41	Delayed methotrexate elimination: Incidence, interaction with antacid drugs, and clinical consequences?. <i>Hematological Oncology</i> , 2018, 36, 399-406.	0.8	25
42	Prognostic Impact of 18F-FDG PET/CT in Patients With Aggressive B-Cell Lymphoma Treated With Anti-CD19 Chimeric Antigen Receptor T Cells. <i>Clinical Nuclear Medicine</i> , 2021, 46, 627-634.	0.7	25
43	Identification of MUM1 as a prognostic immunohistochemical marker in follicular lymphoma using computerized image analysis. <i>Human Pathology</i> , 2014, 45, 2085-2093.	1.1	23
44	Glofitamab Step-up Dosing Induces High Response Rates in Patients (pts) with Relapsed or Refractory (R/R) Mantle Cell Lymphoma (MCL), Most of Whom Had Failed Prior Bruton's Tyrosine Kinase Inhibitor (BTKi) Therapy. <i>Blood</i> , 2021, 138, 130-130.	0.6	23
45	Genome-wide CRISPR screen identifies CDK6 as a therapeutic target in adult T-cell leukemia/lymphoma. <i>Blood</i> , 2022, 139, 1541-1556.	0.6	23
46	Molecular Classification of Diffuse Large B-cell Lymphoma. <i>Hematology/Oncology Clinics of North America</i> , 2016, 30, 1163-1177.	0.9	22
47	Mosunetuzumab in Combination with Lenalidomide Has a Manageable Safety Profile and Encouraging Activity in Patients with Relapsed/Refractory Follicular Lymphoma: Initial Results from a Phase Ib Study. <i>Blood</i> , 2021, 138, 129-129.	0.6	21
48	Droplet digital PCR allows vector copy number assessment and monitoring of experimental CAR T cells in murine xenograft models or approved CD19 CAR T cell-treated patients. <i>Journal of Translational Medicine</i> , 2021, 19, 265.	1.8	20
49	CD1d-restricted peripheral T cell lymphoma in mice and humans. <i>Journal of Experimental Medicine</i> , 2016, 213, 841-857.	4.2	19
50	High-dose therapy and autologous stem cell transplantation in marginal zone lymphomas: a retrospective study by the EBMT Lymphoma Working Party and FIL-GITMO. <i>British Journal of Haematology</i> , 2018, 182, 807-815.	1.2	19
51	Long-term outcomes of adults with first-relapsed/refractory systemic anaplastic large-cell lymphoma in the pre-brentuximab vedotin era: A LYSA/SFGM-TC study. <i>European Journal of Cancer</i> , 2017, 83, 146-153.	1.3	18
52	Hepatitis C virus infection and lymphoma. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2010, 2, e2010004.	0.5	18
53	Obinutuzumab plus lenalidomide in advanced, previously untreated follicular lymphoma in need of systemic therapy: a LYSA study. <i>Blood</i> , 2022, 139, 2338-2346.	0.6	18
54	Quantitative and functional analyses of CD4 ⁺ CD25 ⁺ FoxP3 ⁺ regulatory T cells in chronic phase chronic myeloid leukaemia patients at diagnosis and on imatinib mesylate. <i>British Journal of Haematology</i> , 2011, 153, 139-143.	1.2	17

#	ARTICLE	IF	CITATIONS
55	Are We Nearing an Era of Chemotherapy-Free Management of Indolent Lymphoma?. <i>Clinical Cancer Research</i> , 2014, 20, 5226-5239.	3.2	17
56	Treatment Approach to Newly Diagnosed Diffuse Large B-Cell Lymphoma. <i>Seminars in Hematology</i> , 2015, 52, 107-118.	1.8	16
57	Residual Activatability of Circulating Tfh17 Predicts Humoral Response to Thymodependent Antigens in Patients on Therapeutic Immunosuppression. <i>Frontiers in Immunology</i> , 2018, 9, 3178.	2.2	16
58	CAR-T cells, from principle to clinical applications. <i>Bulletin Du Cancer</i> , 2021, 108, S4-S17.	0.6	15
59	Bendamustine for the treatment of relapsed or refractory peripheral T cell lymphomas: A French retrospective multicenter study. <i>Oncotarget</i> , 2016, 7, 85573-85583.	0.8	13
60	Glofitamab As Monotherapy and in Combination with Obinutuzumab Induces High Complete Response Rates in Patients (pts) with Multiple Relapsed or Refractory (R/R) Follicular Lymphoma (FL). <i>Blood</i> , 2021, 138, 128-128.	0.6	13
61	Immunoarchitectural patterns in splenic marginal zone lymphoma: correlations with chromosomal aberrations, <i>IGHV</i> mutations, and survival. A study of 76 cases. <i>Histopathology</i> , 2013, 62, 876-893.	1.6	12
62	SMABcare study: subcutaneous monoclonal antibody in cancer care: cost-consequence analysis of subcutaneous rituximab in patients with follicular lymphoma. <i>Annals of Hematology</i> , 2018, 97, 123-131.	0.8	12
63	Thromboembolic events and thromboprophylaxis associated with immunomodulators in multiple myeloma patients: a real-life study. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, 148, 975-984.	1.2	12
64	Plasticity of Mature B Cells Between Follicular and Classic Hodgkin Lymphomas. <i>American Journal of Surgical Pathology</i> , 2022, 46, 58-70.	2.1	12
65	Autologous EBV-specific T cell treatment results in sustained responses in patients with advanced extranodal NK/T lymphoma: results of a multicenter study. <i>Annals of Hematology</i> , 2021, 100, 2529-2539.	0.8	12
66	Long-Term Follow-up Analysis of ZUMA-5: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory (R/R) Indolent Non-Hodgkin Lymphoma (iNHL). <i>Blood</i> , 2021, 138, 93-93.	0.6	12
67	Marrow-ablative treatment and autologous stem cell transplantation in follicular NHL. <i>Best Practice and Research in Clinical Haematology</i> , 2011, 24, 257-270.	0.7	11
68	Immunosuppression Is Associated With Clinical Features and Relapse Risk of B Cell Posttransplant Lymphoproliferative Disorder: A Retrospective Analysis Based on the Prospective, International, Multicenter PTLTD-1 Trials. <i>Transplantation</i> , 2018, 102, 1914-1923.	0.5	11
69	Array-CGH predicts prognosis in plasma cell posttransplantation lymphoproliferative disorders. <i>Genes Chromosomes and Cancer</i> , 2017, 56, 221-230.	1.5	10
70	Rapamycin safeguards lymphocytes from DNA damage accumulation in vivo. <i>European Journal of Cell Biology</i> , 2016, 95, 331-341.	1.6	9
71	Early-onset severe infections in allogeneic hematopoietic stem cell transplantation recipients with graft failure. <i>American Journal of Hematology</i> , 2019, 94, E109-E111.	2.0	9
72	Single-agent ibrutinib in RESONATE-2, and RESONATE, versus treatments in the real-world PHEDRA databases for patients with chronic lymphocytic leukemia. <i>Annals of Hematology</i> , 2019, 98, 2749-2760.	0.8	9

#	ARTICLE	IF	CITATIONS
73	Kte-X19 in Relapsed or Refractory Mantle-Cell Lymphoma, a "Real-Life" Study from the Descar-T Registry and Lysa Group. <i>Blood</i> , 2021, 138, 743-743.	0.6	9
74	Chemotherapy-free treatment in patients with follicular lymphoma. <i>Expert Review of Hematology</i> , 2015, 8, 187-203.	1.0	8
75	Radioimmunotherapy-augmented BEAM chemotherapy vs BEAM alone as the high-dose regimen for autologous stem cell transplantation (ASCT) in relapsed follicular lymphoma (FL): a retrospective study of the EBMT Lymphoma Working Party. <i>Bone Marrow Transplantation</i> , 2017, 52, 1120-1125.	1.3	8
76	Real-life targeted next-generation sequencing for lymphoma diagnosis over 1 year from the French Lymphoma Network. <i>British Journal of Haematology</i> , 2021, 193, 1110-1122.	1.2	8
77	New Insights into the Biology and Diagnosis of Splenic Marginal Zone Lymphomas. <i>Current Oncology</i> , 2021, 28, 3430-3447.	0.9	8
78	Lenalidomide in Combination with CHOP in Patients with Angioimmunoblastic T-Cell Lymphoma (AITL): Final Analysis of Clinical and Molecular Data of a Phase 2 Lysa Study. <i>Blood</i> , 2018, 132, 999-999.	0.6	8
79	Clinical Outcome of 27 Imatinib Mesylate Resistant Chronic Myelogenous Leukemia (CML) Patients Harboring a T315I BCR-ABL Mutation.. <i>Blood</i> , 2006, 108, 2190-2190.	0.6	8
80	Efficacy of Tisagenlecleucel in Adult Patients (Pts) with High-Risk Relapsed/Refractory Follicular Lymphoma (r/r FL): Subgroup Analysis of the Phase II Elara Study. <i>Blood</i> , 2021, 138, 131-131.	0.6	8
81	Etoposide pharmacokinetics impact the outcomes of lymphoma patients treated with BEAM regimen and ASCT: a multicenter study of the LYmphoma Study Association (LYSA). <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 76, 939-948.	1.1	7
82	A Propensity Score-Matched Comparison of Axi-Cel and Tisa-Cel for Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Real-Life: A Lysa Study from the Descar-T Registry. <i>Blood</i> , 2021, 138, 92-92.	0.6	7
83	CAR-T cell: Toxicities issues: Mechanisms and clinical management. <i>Bulletin Du Cancer</i> , 2021, 108, S117-S127.	0.6	7
84	Actinomycosis after allogeneic hematopoietic stem cell transplantation despite penicillin prophylaxis. <i>Transplant Infectious Disease</i> , 2016, 18, 595-600.	0.7	6
85	Early progression of disease in follicular lymphoma is a robust correlate but not a surrogate for overall survival. <i>Blood Advances</i> , 2021, 5, 1729-1732.	2.5	6
86	Autologous stem cell transplantation for post-transplant lymphoproliferative disorders after solid organ transplantation: a retrospective analysis from the Lymphoma Working Party of the EBMT. <i>Bone Marrow Transplantation</i> , 2021, 56, 2118-2124.	1.3	6
87	Time has come for immunotherapy in PTCL. <i>Blood</i> , 2014, 123, 3059-3060.	0.6	5
88	rituximab use is safe and does not impact prognosis in patient with de novo follicular lymphoma treated with immunochemotherapy: an exploratory analysis of the PRIMA cohort study. <i>American Journal of Hematology</i> , 2016, 91, 410-415.	2.0	5
89	Refractory diffuse large B-cell lymphoma after first-line immuno-CT: Treatment options and outcomes. <i>Hematological Oncology</i> , 2018, 36, 533-542.	0.8	5
90	Controversies in the Treatment of Peripheral T-cell Lymphoma. <i>HemaSphere</i> , 2020, 4, e461.	1.2	5

#	ARTICLE	IF	CITATIONS
91	Extracorporeal cytokine adsorption for treating severe refractory cytokine release syndrome (CRS). Bone Marrow Transplantation, 2020, 55, 2052-2055.	1.3	5
92	Outcome after hematopoietic stem cell transplantation in patients with extranodal natural killer/Cell lymphoma, nasal type: A French study from the Soci�t� Francophone de Greffe de Moelle et de Therapie Cellulaire (SFGM�C). American Journal of Hematology, 2021, 96, 834-845.	2.0	5
93	Adverse outcome in follicular lymphoma is associated with MYC rearrangements but not MYC extra copies. British Journal of Haematology, 2021, 194, 382-392.	1.2	5
94	Long Term Follow-up of the GELF86 French and Belgian Trials: Complete Remission after First Line Treatment with Conventional Chemotherapy in Newly Diagnosed Follicular Lymphoma Patients Correlates with Prolonged Overall Survival Compared with Partial Remission. Blood, 2008, 112, 2590-2590.	0.6	5
95	Outcome of Relapsed/Refractory Aggressive B-Cell Lymphoma Patients Relapsing after Anti-CD19 CAR T-Cells and Enrolled in the Descar-T French National Registry. Blood, 2021, 138, 885-885.	0.6	5
96	Clinical Activity of CC-99282, a Novel, Oral Small Molecule Cereblon E3 Ligase Modulator (CELMoD) Agent, in Patients (Pts) with Relapsed or Refractory Non-Hodgkin Lymphoma (R/R NHL) - First Results from a Phase 1, Open-Label Study. Blood, 2021, 138, 3574-3574.	0.6	5
97	HLA-DR expression on monocytes and outcome of anti-CD19 CAR T-cell therapy for large B-cell lymphoma. Blood Advances, 2023, 7, 744-755.	2.5	5
98	Chronic Borrelia burgdorferi infection triggers NKT lymphomagenesis. Blood, 2018, 132, 2691-2695.	0.6	4
99	Parameters influencing the pharmacokinetics/pharmacodynamics of piperacillin/tazobactam in patients with febrile neutropenia and haematological malignancy: a prospective study. Journal of Antimicrobial Chemotherapy, 2019, 74, 2676-2680.	1.3	4
100	Chronic T cell receptor stimulation unmasks NK receptor signaling in peripheral T cell lymphomas via epigenetic reprogramming. Journal of Clinical Investigation, 2021, 131, .	3.9	4
101	Clinical characteristics and outcomes of relapsed follicular lymphoma after autologous stem cell transplantation in the rituximab era. Hematological Oncology, 2020, 38, 137-145.	0.8	3
102	Characteristics of T- and NK-cell Lymphomas After Renal Transplantation: A French National Multicentric Cohort Study. Transplantation, 2021, 105, 1858-1868.	0.5	3
103	Validation of the PRIMA-Prognostic Index for Patients Treated with Rituximab Plus Chemotherapy and Refinement of Prognostic Parameters for Patients on Rituximab Plus Lenalidomide in the Phase III Relevance Trial. Blood, 2019, 134, 1524-1524.	0.6	3
104	Efficacy and Safety of Thalidomide In Mantle Cell Lymphoma: Results of the French ATU Program.. Blood, 2010, 116, 1794-1794.	0.6	3
105	What Is the Best First-Line Treatment Strategy for Patients with Indolent Lymphomas?. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2012, , 488-493.	1.8	3
106	Six-Year Results from the Phase 3 Randomized Study Relevance Show Similar Outcomes for Previously Untreated Follicular Lymphoma Patients Receiving Lenalidomide Plus Rituximab (R 2) Versus Rituximab-Chemotherapy Followed By Rituximab Maintenance. Blood, 2021, 138, 2417-2417.	0.6	3
107	Assessment of Patient Reported Outcomes (PROs) in Outpatients Taking Oral Anticancer Drugs Included in the Real-Life Oncoral Program. Cancers, 2022, 14, 660.	1.7	3
108	Tislelizumab, a PD-1 inhibitor for relapsed/refractory mature T/NK-cell neoplasms: Results from a phase 2 study.. Journal of Clinical Oncology, 2022, 40, 7552-7552.	0.8	3

#	ARTICLE	IF	CITATIONS
109	Combination therapy for relapsed peripheral T-cell lymphoma: is two better than one?. <i>Lancet Haematology</i> , 2015, 2, e307-e308.	2.2	2
110	Breast implant-associated anaplastic large cell lymphoma. <i>Blood Research</i> , 2019, 54, 3-3.	0.5	2
111	Phase III Clinical Trials in First-Line Follicular Lymphoma: A Review of Their Design and Interpretation. <i>Advances in Therapy</i> , 2021, 38, 3489-3505.	1.3	2
112	CAUSE OF DEATH IN FOLLICULAR LYMPHOMA IN THE RITUXIMAB ERA: A POOLED ANALYSIS OF FRENCH AND US COHORTS. <i>Hematological Oncology</i> , 2017, 35, 34-35.	0.8	1
113	PD-1 BLOCKADE IN A FRENCH SERIES OF 13 RELAPSED / REFRACTORY NK/T-CELL LYMPHOMA PATIENTS. <i>Hematological Oncology</i> , 2019, 37, 272-273.	0.8	1
114	S1600 REAL-WORLD RESULTS ON CD19 CAR T-CELL FOR 60 FRENCH PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA INCLUDED IN A TEMPORARY AUTHORIZATION FOR USE (ATU) PROGRAM. <i>HemaSphere</i> , 2019, 3, 736-737.	1.2	1
115	Reply to S. Fuji. <i>Journal of Clinical Oncology</i> , 2020, 38, 523-523.	0.8	1
116	Monitoring Asparaginase Activity in 21 Patients with Extranodal NK/T-Cell Lymphoma Shows a Very High Proportion of Asparaginase Inactivation. <i>Blood</i> , 2018, 132, 5351-5351.	0.6	1
117	Chromatin Accessibility Profiling to Increase Diagnostic Accuracy and Refine Cell-of-Origin Classification of Mature T-Cell Lymphomas. <i>Blood</i> , 2021, 138, 809-809.	0.6	1
118	ROLE OF UP-FRONT AUTOLOGOUS STEM CELL TRANSPLANTATION IN PERIPHERAL T-CELL LYMPHOMAS: a PROPENSITY SCORE MATCHING ANALYSIS OF PATIENTS FROM LYSA CENTERS. <i>Hematological Oncology</i> , 2017, 35, 76-77.	0.8	0
119	INTEGRATIVE ANALYSIS OF FEATURES ASSOCIATED WITH TET2, IDH2, DNMT3A, AND RHOA MUTATIONS IN ANGIOIMMUNOBLASTIC T CELL LYMPHOMA: A LYSA STUDY. <i>Hematological Oncology</i> , 2017, 35, 165-167.	0.8	0
120	CHARACTERISTICS AND OUTCOMES OF RELAPSED FOLLICULAR LYMPHOMA AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION IN THE RITUXIMAB ERA. <i>Hematological Oncology</i> , 2017, 35, 220-221.	0.8	0
121	Unravelling Subtleties of Angioimmunoblastic T-Cell Lymphoma. <i>Journal of Oncology Practice</i> , 2019, 15, 147-148.	2.5	0
122	ONE-YEAR REAL-LIFE TARGETED NEXT GENERATION SEQUENCING FOR LYMPHOMA DIAGNOSIS: STUDY OF PATIENTS FROM THE FRENCH LYMPHOMA NETWORK IN RHÔNE-ALPES. <i>Hematological Oncology</i> , 2019, 37, 186-186.	0.8	0
123	Poster:ABCL-360 Glofitamab Step-Up Dosing (SUD): Updated Efficacy Data Show High Complete Response Rates in Heavily Pretreated Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL) Patients (Pts). <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, S243.	0.2	0
124	Poster: IBCL-195: Primary Analysis of the Phase 2 ELARA Trial: Tisagenlecleucel Efficacy and Safety in Adult Patients with Relapsed/Refractory Follicular Lymphoma (r/r FL). <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, S245.	0.2	0
125	IBCL-195: Primary Analysis of the Phase 2 ELARA Trial: Tisagenlecleucel Efficacy and Safety in Adult Patients with Relapsed/Refractory Follicular Lymphoma (r/r FL). <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, S403-S404.	0.2	0
126	The Proportion of Natural Regulatory T-Cells CD4+CD25+Foxp3+ in Chronic Phase Chronic Myelogenous Leukemia Patients Correlates with Sokal Score at Diagnosis and Is Increased during Imatinib Mesylate Treatment.. <i>Blood</i> , 2007, 110, 2933-2933.	0.6	0

#	ARTICLE	IF	CITATIONS
127	Hodgkin Variant of Richter's Syndrome: Report of 34 Cases. A Role of EBV in Transformation.. Blood, 2009, 114, 1550-1550.	0.6	0
128	P53 Prevents TCR-Dependent Peripheral T-Cell Lymphomagenesis From Chronically Stimulated T Cells.. Blood, 2012, 120, 2401-2401.	0.6	0
129	Absence of Prognostic Impact Associated with the Use of Statins in Patients with Follicular Lymphoma in the Rituximab Era: An Exploratory Analysis From the PRIMA Study.. Blood, 2012, 120, 2649-2649.	0.6	0
130	A New Prognostic Score for Patients Older Than 60 Years with a Classical Hodgkin Lymphoma: A Retrospective Analysis on 165 Patients. Blood, 2014, 124, 1721-1721.	0.6	0
131	Identification of Previously Unrecognized CD1d-Restricted Peripheral T Cell Lymphomas (PTCLs) in Mouse and Human Reveals Blocking Anti-CD1d Monoclonal Antibodies As a New Therapeutic Possibility in PTCLs. Blood, 2014, 124, 4485-4485.	0.6	0
132	Bendamustine Treatment in Refractory or Relapsed T Cell Lymphomas: A Retrospective Multicenter Study. Blood, 2015, 126, 1505-1505.	0.6	0
133	Single-Agent Ibrutinib Vs Standard of Care for Patients with Relapsed/Refractory (R/R) and Treatment-Naive (TN) Chronic Lymphocytic Leukemia (CLL): An Adjusted Comparison of RESONATE™ and RESONATE-2™ with the French Lyon-Sud Database. Blood, 2016, 128, 2039-2039.	0.6	0
134	A New Simplified Prognostic Index Integrating the Type of Extra-Nodal Involvement and Age for Ann Arbor Stage IV Hodgkin Lymphoma Patients Diagnosed at TEP-Scanner Era: A Retrospective Analysis from Lymphoma Study Association (LYSA) Centers. Blood, 2018, 132, 1629-1629.	0.6	0
135	Efficacy of Systemic Therapies for Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (R/R iNHL): A Systematic Literature Review (SLR). Blood, 2018, 132, 2266-2266.	0.6	0
136	Breast Implant Associated-Anaplastic Large Cell Lymphoma (BIA-ALCL): The French Lymphoma Study Association (LYSA) Registry Data. Blood, 2018, 132, 1641-1641.	0.6	0
137	Rituximab in Combination with Adapted-Dose of Ifosfamide and Etoposide As Salvage Treatment in Elderly Refractory/Relapsed Diffuse Large B-Cell Lymphoma Patients Non-Candidate for High Dose Therapy: A Retrospective Study of Lyon Hospital University. Blood, 2018, 132, 4215-4215.	0.6	0
138	Breast Implant Associated-Anaplastic Large Cell Lymphoma (BIA-ALCL): The Lymphoma Study Association (LYSA) Registry Data. Blood, 2019, 134, 4021-4021.	0.6	0
139	Genome-Wide CRISPR Library Screening Identifies CDK6 As Genetic Vulnerability in Adult T-Cell Leukemia/Lymphoma. Blood, 2019, 134, 3781-3781.	0.6	0
140	Interpreting results in clinical trials and subgroup analyzes. Hematologie, 2019, 25, 3-10.	0.0	0
141	Rituximab in combination with adapted-dose of ifosfamide and etoposide as salvage treatment in elderly refractory/relapsed diffuse large B-cell lymphoma patients non-candidate for high dose therapy: a retrospective study. Leukemia and Lymphoma, 2022, 63, 599-607.	0.6	0
142	Breast Implant Associated-Anaplastic Large-Cell Lymphoma (BIA-ALCL): Data Based on the Lymphoma Study Association (LYSA) Registry. Promising Results of Brentuximab Vedotin Combined with Cyclophosphamide, Doxorubicin and Prednisone (BV-CHP) As First Line Treatment for Patient Requiring Chemotherapy. Blood, 2021, 138, 1387-1387.	0.6	0
143	The upper ECHELON against T-cell lymphoma. Annals of Oncology, 2022, 33, 239-241.	0.6	0